IRADIMED CEO linked trust sells 7,500 shares
IRADIMED CORP director and CEO Roger E. Susi reported pre-planned insider sales of common stock.
Rhea-AI Filing Summary
IRADIMED CORP director and CEO Roger E. Susi reported pre-planned insider sales of common stock. Entities associated with him, specifically the Phillip Susi 2008 Dynasty Trust, sold a total of 7,500 shares of IRMD common stock in open-market transactions on May 11 and May 12 under a Rule 10b5-1 trading plan adopted on November 5, 2025. The sales occurred at weighted-average prices around the mid-$80s per share, with execution ranges from $83.11 to $86.00. The filing also records indirect holdings of 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust and 162,950 shares by the Roger E. Susi Revocable Trust as of May 11, reflecting additional indirect ownership structures.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 7,500 shares
Net Sell
7 txns
Insider
Susi Roger E.
Role
CEO, President, Chairman
Sold
7,500 shs ($631K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 3,307 | $83.70 | $277K |
| Sale | Common Stock | 1,104 | $84.59 | $93K |
| Sale | Common Stock | 1,773 | $84.08 | $149K |
| Sale | Common Stock | 1,001 | $84.94 | $85K |
| Sale | Common Stock | 315 | $85.90 | $27K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 2,180,000 shares (Indirect, By Phillip Susi 2008 Dynasty Trust);
Common Stock — 162,950 shares (Indirect, By Roger E. Susi Revocable Trust);
Common Stock — 2,062,500 shares (Indirect, By Matthew Susi 2008 Dynasty Trust)
Footnotes (7)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $83.66 to $84.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $84.73 to $85.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $85.78 to $86.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $83.11 to $84.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $84.17 to $84.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose.
Key Figures
Shares sold: 7,500 shares
Sale price May 12 block: $84.59 per share
Sale price May 12 block: $83.70 per share
+4 more
7 metrics
Shares sold
7,500 shares
Total common shares sold indirectly via Phillip Susi 2008 Dynasty Trust
Sale price May 12 block
$84.59 per share
Weighted-average price for 1,104 shares sold on May 12
Sale price May 12 block
$83.70 per share
Weighted-average price for 3,307 shares sold on May 12
Sale price May 11 blocks
$85.90 / $84.94 / $84.08
Weighted-average prices for 315, 1,001 and 1,773 shares sold on May 11
Price ranges
$83.11–$86.00 per share
Execution ranges across multiple trades in the reported sales
Matthew Susi 2008 Dynasty Trust holding
2,062,500 shares
Indirect common stock holding as of May 11
Roger E. Susi Revocable Trust holding
162,950 shares
Indirect common stock holding as of May 11
Key Terms
Rule 10b5-1 trading plan, weighted average sale price, Dynasty Trust, Revocable Trust, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
Dynasty Trust financial
"nature_of_ownership: By Phillip Susi 2008 Dynasty Trust"
Revocable Trust financial
"nature_of_ownership: By Roger E. Susi Revocable Trust"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
Section 16 regulatory
"shall not be deemed an admission of beneficial ownership of all the reported shares for purposes of Section 16 or for any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did IRADIMED (IRMD) report for Roger E. Susi?
The filing shows entities associated with Roger E. Susi sold 7,500 IRADIMED common shares in the open market. These were indirect sales through the Phillip Susi 2008 Dynasty Trust, spread over May 11 and May 12 at prices in the $80s per share.
Were Roger E. Susi’s IRADIMED (IRMD) stock sales pre-planned under a Rule 10b5-1 plan?
Yes. The filing states the sales were executed under a Rule 10b5-1 trading plan adopted on November 5, 2025. Such plans pre-schedule trades, indicating these dispositions followed a predetermined program rather than discretionary market timing decisions.
Through which entities were the IRADIMED (IRMD) insider sales and holdings reported?
The reported sales were made indirectly through the Phillip Susi 2008 Dynasty Trust. The filing also lists indirect holdings of 2,062,500 shares by the Matthew Susi 2008 Dynasty Trust and 162,950 shares by the Roger E. Susi Revocable Trust as of May 11.
Does the IRADIMED (IRMD) Form 4 show any option exercises or derivative transactions?
No. The transaction summary indicates zero derivative exercises, with no options or other derivatives reported. All listed trades involve non-derivative common stock, and the derivative position summary is empty, focusing this filing purely on common-share holdings and sales.
AI-generated analysis. How Rhea-AI works. Not financial advice.
